Novo Holdings A/S’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Novo Holdings A/S’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-225,000	Closed	-$4.07M	–	24
2018 Q3	$4.07M	Sell	225,000 -1,240,838	-85%	-$14.7M	0.32%	22
2018 Q2	$14.6M	Hold	1,465,838	–	–	1.47%	10
2018 Q1	$7.78M	Sell	1,465,838 -565,724	-28%	-$4.04M	0.98%	15
2017 Q4	$17.3M	Hold	2,031,562	–	–	2.42%	8
2017 Q3	$29.7M	Hold	2,031,562	–	–	3.86%	8
2017 Q2	$38.1M	Hold	2,031,562	–	–	4.56%	7
2017 Q1	$43.3M	Hold	2,031,562	–	–	4.61%	6
2016 Q4	$30.9M	Buy	+2,031,562	New	+$27.6M	2.94%	9

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MMPI

Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Novo Holdings A/S's RARX Position: Q4 2018 in Review

Novo Holdings A/S sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2018, closing a stake of 225,000 shares — an estimated $4.07M sold.

Novo Holdings A/S first reported a position in RARX in Q4 2016 and held it in 8 quarters. The position peaked at $43.3M in Q1 2017. 94 funds tracked by Wall St. Rank hold RARX as of Q4 2018.

Novo Holdings A/S reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Novo Holdings A/S sold 225,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $4.07M.
Novo Holdings A/S first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
Novo Holdings A/S's Ra Pharmaceuticals, Inc. Common Stock position peaked at $43.3M in Q1 2017.
94 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Novo Holdings A/S's 13F filing for Q4 2018, filed 14 Feb 2019.